| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT06616155 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for NCT06931340 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Not Yet Recruiting | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients NCT07200830 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistan NCT06236139 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, NCT06039371 | University of Washington | Phase 2 |
| Active Not Recruiting | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mu NCT05689021 | Mayo Clinic | Phase 2 |
| Withdrawn | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients NCT05156372 | The University of Texas Health Science Center at San Antonio | N/A |
| Terminated | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Se NCT05733351 | Emory University | Phase 1 |
| Suspended | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prost NCT05445609 | Emory University | Phase 2 |
| Recruiting | Measuring Oncological Value of Exercise and Statin NCT05796973 | Tampere University Hospital | Phase 3 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT05479578 | Rashmi Verma, MD | Phase 1 |
| Recruiting | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT04704505 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoC NCT05168618 | University of Utah | Phase 2 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate C NCT04455750 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer NCT04781374 | Beth Israel Deaconess Medical Center | Phase 2 |
| Recruiting | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prosta NCT04734730 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer NCT03902951 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT04471974 | Rahul Aggarwal | Phase 2 |
| Completed | Evaluation of PSMA Antagonist Produced by Two Different Methods NCT04685811 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Recruiting | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor M NCT05054296 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer NCT06850545 | Kuopio University Hospital | — |
| Active Not Recruiting | A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer NCT04190446 | Mayo Clinic | Phase 2 |
| Unknown | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT04033432 | Northwestern University | Phase 2 |
| Active Not Recruiting | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With NCT03317392 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE NCT03611686 | University Hospital, Rouen | — |
| Completed | Tumor Molecular Profiling in Patients With Prostate Cancer NCT05573789 | Hellenic Cooperative Oncology Group | — |
| Completed | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide NCT02099864 | OHSU Knight Cancer Institute | Phase 2 |